



TFW 7625

TRANSMITTAL LETTER #General - Patent Pending)	Docket No. 19710
--	---------------------

In Re Application Of: Elfi Biedermann et al.

Application No. 09/595,218	Filing Date June 16, 2000	Examiner Zinna Northington Davis	Customer No. 23389	Group Art Unit 1625	Confirmation No. 2204
-------------------------------	------------------------------	-------------------------------------	-----------------------	------------------------	--------------------------

Title: CYCLIC IMIDE-SUBSTITUTED PYRIDYLALANE, ALKENE, ALKINE, CARBOBOXAMIDES
USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS


COMMISSIONER FOR PATENTS:

Transmitted herewith is:

**Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address
Statement Under 37 C.F.R. 3.73 (b) with copy of original Assignment attached**


in the above identified application.

- ☒ No additional fee is required.
 - ☐ A check in the amount of _____ is attached.
 - ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
 - ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☒ Charge any additional fee required.
 - ☐ Payment by credit card. Form PTO-2038 is attached.
- WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**


Signature

Dated: July 17, 2006

Mark J. Cohen
Registration No. 32,211
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
July 17, 2006 (Date)	
Signature of Person Mailing Correspondence Mark J. Cohen	
Typed or Printed Name of Person Mailing Correspondence	

cc:


Doc Code:

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/82 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/595,218
Filing Date	June 16, 2000
First Named Inventor	Elfi Biedermann
Art Unit	1625
Examiner Name	Zinna Northington Davis
Attorney Docket Number	19710

I hereby revoke all previous powers of attorney given in the above-identified application:

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

00272

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with
Customer Number:

23389

OR

☐ Firm or
Individual Name

Address

City

State

ZIP

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71
Statement under 37CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature

Name

Date


Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Doc Code JUL 21 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/96 (12-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Astellas Pharma GmbH

Application No./Patent No./Control No.: 09/595,218

Filed/Issue Date: June 16, 2000

Entitled: CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, ALKINE CARBOXAMIDES
USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS

Astellas Pharma GmbH

, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at _____, Frame _____, or a true copy of the original is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Katrin Becker

Signature

Katrin Becker

Printed or Typed Name

Director Legal Affairs

Title

July 6, 2006

Date

+49 89 4544-2062

Telephone number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

A S S I G N M E N T

WE, ELFI BIEDERMANN, residing in Vaterstetten, Germany; MAX HASMANN, residing in Neuried, Germany; ROLAND LÖSER, residing in Feldafing, Germany; BENNO RATTEL, residing in Munich, Germany; FRIEDEMANN REITER residing in Putzbrunn, Germany; BARBARA SCHEIN residing in Neufahrn, Germany; KLAUS SEIBEL residing in Grafelfing, Germany; KLAUS VOGT residing in Munich, Germany; KATJA WOSIKOWSKI residing in Poing, Germany; and ISABEL SCHMAINDA residing in Munich, Germany, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned and do hereby assign to Klinge Pharma GmbH, having a principle place of business at Berg-am-Laim-Strasse 129, D-81673 Munich, Germany, its successors, assigns and legal representatives (Assignee), the entire right, title and interest in and to all subject matter invented by us and disclosed in U.S. Application No. 09/595,218, which is a continuation of International Patent Application No. PCT/EP98/08267, filed 16 December 1998, entitled

**CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE,
ALKENE AND ALKINE CARBOXAMIDES USEFUL A
CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS**

and in and to all Patent and all Convention and Treaty rights of all kinds including the rights to claim priority therefrom, in the United States of America, for all such subject matter. We agree to sign all documents necessary to secure all said Patents and rights, and request issuance of all said Patents to the above assignee in accordance with this request.

25.10. , 2000


Elfi Biedermann

25.10. , 2000


Max Hasmann

ASSIGNMENT

Atty. Dkt. No. 69053

25.10., 2000

R. Löser
Roland Löser

25.10., 2000

B. Rattel
Benno Rattel

25.10., 2000

F. Reiter
Friedemann Reiter

25.10., 2000

Barbara Schein
Barbara Schein

25.10., 2000

K. Seibel
Klaus Seibel

25.10., 2000

K. Vogt
Klaus Vogt

25.10., 2000

Katja Wosikowski
Katja Wosikowski

25.10., 2000

Isabel Schemainda
Isabel Schemainda